Helen Torley sold $6.4M of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 60,000 shares at an average of $107.28, traded Sep 9, 2026, filed Sep 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$6.4M at market
- 0Share of holdings soldSold 7.6% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-26-000119, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $18.41 | $368k | 787,780 | 31 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -13,304 | $107.22 | $1.4M | 774,476 | 31 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -6,596 | $107.82 | $711k | 767,880 | 31 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $108.67 | $11k | 767,780 | 31 d ago |
| Sep 10, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $18.41 | $368k | 787,780 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stock10b5-1 | -14,588 | $107.01 | $1.6M | 773,192 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stock10b5-1 | -5,412 | $107.58 | $582k | 767,780 | 31 d ago |
| Sep 11, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $18.41 | $368k | 787,780 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -15,492 | $107.15 | $1.7M | 772,288 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -4,508 | $107.55 | $485k | 767,780 | 31 d ago |
| Sep 9, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $18.41 | $368k | 121,552 | 31 d ago |
| Sep 10, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $18.41 | $368k | 101,552 | 31 d ago |
| Sep 11, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $18.41 | $368k | 81,552 | 31 d ago |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 37Weak | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $278k 4,263 shares | -25% | |
| 2Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $59k 829 shares | -2% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $137k 2,000 shares | -4% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $150k 2,000 shares | -4% | |
| 21Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $174k 2,227 shares | -9% | |
| 37Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $1.5M 20,000 shares | -45% | |
| 30Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $4.4M 60,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.